<DOC>
	<DOCNO>NCT03027934</DOCNO>
	<brief_summary>The overall objective study ass P2Y12 inhibition ex vivo blood sample obtain diabetic subject administer one two P2Y12 antagonist cross-over design .</brief_summary>
	<brief_title>A Single Center Study Evaluate Ticagrelor Mechanism Action Inhibiting Juvenile Platelet ADP Response</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Male female age 18 70 year , inclusive . 3 . Documented current medical history diabetes control either medication diet and/or exercise . 4 . Women must negative urine pregnancy test . 1 . Pregnant lactating female , female childbearing potential ( i.e. , chemically surgically sterilize postmenopause ) willing use medically accept method contraception consider reliable judgement investigator throughout duration study female positive pregnancy test screening . 2 . Weight le 135 lb . 3 . Currently prescribe take clopidogrel ( generic Plavix ) , ticagrelor ( Brilinta ) prasugrel ( Effient ) take within past 10 day . 4 . Current medication : 1 . PAR1 antagonist ( vorapaxar/Zontivity ) within last month . 2 . Phosphodiesterase inhibitor cilostazol ( Pletal ) . 3 . Glycoprotein IIb/IIIa inhibitor within last ten day ( Integrilin , Aggrastat , ReoPro ) . 4 . Adenosine reuptake inhibitor dipyridamole ( Aggrenox , Persantine ) 5 . Coumadin . 6 . Heparin include low molecular weight heparin . 7 . Factor Xa inhibitor ( e.g. , enoxaparin , rivaroxaban , apixaban , edoxaban ) . 8 . Direct thrombin inhibitor ( e.g. , hirudin , bivalirudin , dabigatran . 9 . Concomitant therapy strong CYP3A inhibitor , atanazavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazadone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole , 10 . Concomitant therapy potent CYP3A inducer , rifampin , phenytoin , carbamazepine , phenobarbital . 5 . Increased bleeding risk include : 1 . Recent ( within 30 day ) GI bleed 2 . Active pathological bleeding 3 . Any history intracranial , intraocular , retroperitoneal , spinal bleeding 4 . Prior history transient ischemic attack stroke 5 . Recent ( within 3 month ) major trauma 6 . Sustained uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180mmHg diastolic blood pressure [ DBP ] &gt; 100mmHg 7 . History hemorrhagic disorder increase risk bleeding ( e.g. , hemophilia , von Willebrand 's disease ) 8 . Patients use within 30 day screen , oral parenteral antithrombotic agent . 9 . Platelet count le 100,000 mm3 hemoglobin &lt; 10g/dL 6 . Contraindication reason ticagrelor prasugrel administer ( e.g. , know hypersensitivity medication medication component ) 7 . A history alcohol and/or substance abuse could interfere conduct trial . 8 . Known active recurrent hepatic disorder ( include cirrhosis , hepatitis B hepatitis C , confirm ( ALT/AST ) level &gt; 3 time ULN total bilirubin &gt; 2 time ULN screening . 9 . Scheduled revascularization ( e.g. , PCI , CABG ) study period . 10 . Any Acute Coronary Syndrome ( ACS ) event within past 6 month . 11 . Participation another investigational drug device study within 30 day dose . 12 . Any acute chronic unstable condition past 30 day condition , opinion investigator , may either put subject risk influence result study ( e.g. , active cancer , risk noncompliance , risk lose followup ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>